Bridgeway Capital Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Bridgeway Capital Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-300	Closed	-$27K	–	1398
2019 Q3	$27K	Hold	300	–	–	﹤0.01%	1298
2019 Q2	$41K	Hold	300	–	–	﹤0.01%	1284
2019 Q1	$82K	Buy	+300	New	+$65K	﹤0.01%	1294
2018 Q4	–	Sell	-500	Closed	-$205K	–	1480
2018 Q3	$205K	Buy	500 +250	+100%	+$116K	﹤0.01%	1318
2018 Q2	$135K	Buy	250 +125	+100%	+$66.5K	﹤0.01%	1344
2018 Q1	$58K	Hold	125	–	–	﹤0.01%	1351
2017 Q4	$84K	Sell	125 -146	-54%	-$88.1K	﹤0.01%	1347
2017 Q3	$171K	Hold	271	–	–	﹤0.01%	1300
2017 Q2	$130K	Hold	271	–	–	﹤0.01%	1340
2017 Q1	$203K	Buy	271 +125	+86%	+$112K	﹤0.01%	1278
2016 Q4	$143K	Sell	146 -40	-22%	-$45.7K	﹤0.01%	1343
2016 Q3	$251K	Hold	186	–	–	﹤0.01%	1277
2016 Q2	$163K	Hold	186	–	–	﹤0.01%	1341
2016 Q1	$260K	Hold	186	–	–	﹤0.01%	1245
2015 Q4	$343K	Buy	186 +39	+27%	+$78K	0.01%	1172
2015 Q3	$287K	Buy	+147	New	+$344K	0.01%	1230

Other funds holding TCON

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Bridgeway Capital Management's TCON Position: Q4 2019 in Review

Bridgeway Capital Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2019, closing a stake of 300 shares — an estimated $27K sold.

Bridgeway Capital Management first reported a position in TCON in Q3 2015 and held it in 16 quarters. The position peaked at $343K in Q4 2015. 15 funds tracked by Wall St. Rank hold TCON as of Q4 2019.

Bridgeway Capital Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Bridgeway Capital Management sold 300 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $27K.
Bridgeway Capital Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2015 and held it in 16 quarters.
Bridgeway Capital Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $343K in Q4 2015.
15 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Bridgeway Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.